Long-Term Responses to Regorafenib in Metastatic Colorectal Cancer Patients Analyzed in New Study

Strategic Insights -

Researchers at Bayer HealthCare Pharmaceuticals Inc. have published a study on the long-term responses of patients with metastatic colorectal cancer (mCRC) treated with regorafenib. The study, published in the journal Cancers, analyzed a database of 2444 patients who initiated regorafenib monotherapy between 2013 and 2023. The research found that patients with long-term responses to regorafenib treatment had favorable performance status at treatment initiation, left-sided tumors, and liver metastases, and had received prior bevacizumab treatment.

Key Takeaways:

  • A total of 544 patients (22%) had a long-term response with regorafenib treatment lasting 4 months or more, 367 patients (15%) had a long-term response with regorafenib treatment lasting 5 months or more, and 250 patients (10%) had a long-term response with regorafenib treatment lasting 6 months or more.
  • Patients with long-term responses to regorafenib treatment had a median age of 66 years, with the majority (65-70%) having left-sided tumors, Eastern Cooperative Oncology Group performance status of 0/1 (67-68%), and liver metastases (55-61%).
  • The median time to regorafenib discontinuation was 6.0-9.3 months among long-term responders.
  • Patients with long-term responses to regorafenib treatment had received prior bevacizumab treatment (60-67%).
  • The study highlights that patients in the real-world setting were able to tolerate and maintain long-term responses to regorafenib treatment.

Statistics:

  • 2444 patients initiated regorafenib monotherapy during the study.
  • 544 patients (22%) with long-term responses had LTR4 (4-month duration), 367 patients (15%) had LTR5 (5-month duration), and 250 patients (10%) had LTR6 (6-month duration).
  • Median age of patients with long-term responses: 66 years.
  • Percentage of patients with left-sided tumors: 65-70%.
  • Percentage of patients with Eastern Cooperative Oncology Group performance status of 0/1: 67-68%.
  • Percentage of patients with liver metastases: 55-61%.
  • Percentage of patients who received prior bevacizumab treatment: 60-67%.

Sources:

  • Real-World Study of Patients with Metastatic Colorectal Cancer and Long-Term Response to Regorafenib in the USA. Cancers, 2025;17(19):3196.
  • NewsRx. New Colon Cancer Study Findings Have Been Reported by Researchers at Bayer HealthCare Pharmaceuticals Inc. (Real-World Study of Patients with Metastatic Colorectal Cancer and Long-Term Response to Regorafenib in the USA). Immunotherapy Weekly. October 29, 2025; p 155.